Streetbeat News

Stock Prices

GP

GreenPower Motor Company Inc (NASDAQ:GP) reported Q4 FY23 revenue of $15.3 million, a 255% Y/Y increase, beating the consensus of $13.98 million. The company delivered 123 vehicles in Q4, generating a gross profit of $2.3 million. At the end of FY23, GP held $41.6 million in inventory. The company has 42 active orders and 141 signed purchase orders for various EV Star models, and 63 active orders for the BEAST and Nano BEAST school buses. GP shares are trading higher by 21.5% at $4.24 premarket.

Portfolio Pulse from Lekha Gupta

July 17, 2023 | 12:58 pm

BLK

COIN

NDAQ

The U.S. Securities and Exchange Commission (SEC) is seeking public input on five Bitcoin ETF applications, including ARK 21Shares Bitcoin ETF by Ark Invest, and ETFs from Wise Origin, WisdomTree, VanEck, and Invesco Galaxy. The SEC also called for comments on the iShares Bitcoin Trust by BlackRock Inc, which was submitted on Nasdaq. In related news, Coinbase shares surged up to 16% last week after striking a deal with Cboe's BZX Exchange regarding the ETF applications.

Portfolio Pulse from Murtuza Merchant

July 17, 2023 | 12:54 pm

F

Ford Motor has announced significant price cuts for all versions of its electric F-150 Lightning pickup, with the cheapest version now starting at about $50,000, a roughly $10,000 cut. The price cuts are a result of Ford's efforts to boost production and lower costs for battery minerals. However, the production increase has not been smooth, with only 4,466 Lightnings sold in the second quarter due to a fire incident that led to a five-week production shutdown.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 12:50 pm

JANX

Janux Therapeutics, Inc. (NASDAQ:JANX) has announced the pricing of an underwritten offering of 4,153,717 shares of its common stock and pre-funded warrants to purchase 583,483 shares at a price of $12.46 per share. The gross proceeds from the offering are expected to be approximately $60 million. The offering is expected to close on July 19, 2023. BofA Securities, Inc. is acting as sole book-runner for the offering.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 12:46 pm

ABOS

BCAN

Several stocks are experiencing significant pre-market movements. Acumen Pharmaceuticals, PainReform, Nova LifeStyle, argenx SE, AERWINS Technologies, BridgeBio Pharma, Nuvve Holding Corp., Cadrenal Therapeutics, Edgio, and Genprex are among the gainers. BYND Cannasoft Enterprises, ViewRay, Ebix, Frequency Therapeutics, Apellis Pharmaceuticals, Minerva Surgical, Baosheng Media Group Holdings, Western Acquisition Ventures Corp., Monopar Therapeutics, and 60 Degrees Pharmaceuticals are among the losers.

Portfolio Pulse from Lisa Levin

July 17, 2023 | 12:45 pm

AAL

JBLU

American Airlines Group Inc (AAL) and JetBlue Airways Corp (JBLU) have begun the process of dissolving their Northeast Alliance, a collaboration formed during the COVID-19 pandemic to share bookings, routes, and passengers. The dissolution comes after the Justice Department sued the airlines in 2021, calling the alliance a 'merger' that resulted in higher costs and fewer options for passengers. JetBlue is focusing on its $3.8 billion acquisition of Spirit Airlines, while American continues to challenge the Northeast Alliance verdict.

Portfolio Pulse from Akanksha Bakshi

July 17, 2023 | 12:41 pm

ABOS

BBIO

GP

Acumen Pharmaceuticals (ABOS) reported positive results from its Phase 1 study of ACU193 for early Alzheimer's disease. BridgeBio (BBIO) announced positive results from its Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy. GreenPower Motor Co (GP) reported Q4 sales of $15.30M, beating estimates of $13.98M.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 12:41 pm

ABOS

Acumen Pharmaceuticals Inc (NASDAQ:ABOS) presented positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, a clinical-stage amyloid beta oligomers (AβO) targeting antibody therapy for early Alzheimer's disease. The results showed that ACU193 was well-tolerated and demonstrated a significant reduction in amyloid plaque load. The company plans to discuss these results with regulators to assess the next steps for the clinical development of ACU193. Following the news, ABOS shares surged 97.40% in the premarket session.

Portfolio Pulse from Vandana Singh

July 17, 2023 | 12:41 pm

EVGN

Trading of Evogene shares has resumed.

Portfolio Pulse from Happy Mohamed

July 17, 2023 | 12:40 pm

ENVB

Enveric Biosciences (NASDAQ:ENVB) has announced positive results from pharmacokinetic animal studies of its lead product candidate, EB-373, a psilocin-prodrug targeting anxiety disorders. The studies demonstrated oral bioavailability, rapid onset of action, systemic clearance, and a favorable side effect profile. The company plans to present thorough analyses of the studies at a future scientific conference.

Portfolio Pulse from Vuk Zdinjak

July 17, 2023 | 12:40 pm